Open Journal of Gastroenterology and Hepatology


EFFICIENCY OF DAA ON HCV-INFECTED KIDNEY TRANSPLANT PATIENTS AT CHO RAY HOSPITAL – VIETNAM

Research Article of Open Journal of Gastroenterology and Hepatology EFFICIENCY OF DAA ON HCV-INFECTED KIDNEY TRANSPLANT PATIENTS AT CHO RAY HOSPITAL - VIETNAM Tran Xuan Truong1, Thai Minh Sam2, Pham Thi Ngoc Thao3, Tran Ngọc Sinh4 1Chief of General Internal Medicin department - Cho Ray hospital – South Vietnam 2Chief of Uro-Neprologic department - Cho Ray hospital – South Vietnam 3Vice Director of Choray hospital-South VietNam 4Uro-Neprology Professor of University of Medical and Pharmaceutical  – South Vietnam Purposes:To evaluate the efficiency of DAA (Direct Antiviral Agent), in particular sofosbuvir, ledipasvir in Hepatitis C treatment for patients with kidney transplants. Take note in the side effects and drug interactions during the treatment processes. Method:Intervention, prospective, cohort, case studies, non-randomized, open on to all kidney transplant cases with chronic Hepatitis C tested positive HCV RNA (+); the patients from the cases above had agreed to be the research’s subjects from 11/2015 to 8/2018 at Cho Ray hospital. Two regimens Sofosbuvir/Ribavirin and Sofosbuvir/Ledipasvir have been used for treatments, which depend on HCV genotype and liver cirrhosis levels. Results:In 440 patients who had been observed after kidney transplants, 44 cases anti HCV (+), 29 cases HCV RNA(+) and 4 cases HBV/HCV Confection. There were 15 cases with chronic Hepatitis C participated in study. Males made up 66.6% of the group with the average age 49± 7.06 yrs. There were 6.7% of them not taking full-course treatments. 80% of the patients were infected with only C virus, while 20% of the patients were co-infected with B and C virus. 40% of them had histories of previous blood transfusions. The ratio of patients with elevated liver enzymes was 33.3%. Genotype 1 (a and b) was 33.3%, genotype 2 was 6.7%, genotype 6 was 53.3% and 6.7% unidentifiable genotype. There were 2 cases which were treated with Sofosbuvir/Ribavirin ...

Inflammatory bowel disease and amebiasis

Review Article of Open Journal of Gastroenterology and Hepatology Inflammatory bowel disease and amebiasis Sanyour Joyce1,  Nakhoul Mary1, Saniour Philippe2, Abou Rached Antoine1 1Lebanese university, school of medicine, Hadath, Beirut 2Saint Joseph Hospital, Dora, Beirut Amebiasis affects around 500 million people in the world. Clinical manifestations of intestinal amebiasis can overlap with symptoms of the inflammatory bowel disease (IBD). Many studies evaluated the relationship of IBD patients during exacerbation periods and amoebic colitis as it is important to rule out the infection before starting steroids and/or immunosuppressive treatment. This mini-review focused on the best strategy to diagnose the infection in this specific population, using classical stool analysis for ova and parasites, serology, investigations by PCR and colonoscopy according to the degree of clinical suspicion. It also suggested an algorithm for management approach where patients were divided into asymptomatic carriers vs. symptomatic patients under 5 ASA or immunosuppressive therapy having either a vegetative or cystic form of the infection. All these patients were treated accordingly by intraluminal agents, and nitroimidazole was added in the vegetative form. 5-ASA was not a contraindication for treatment, while immunosuppression is forbidden until after eradiation of EH. Amoebic infection should always be ruled out before starting treatment with steroid or immunosuppressive medications, in order to minimize its deleterious outcomes on IBD patients. Keywords: Inflammatory bowel disease, amebiasis, review ...

Study of the effect of sofosbuvir and daklatasivir on respiratory system in patients with chronic hepatitis C

Research Article of Open Journal of Gastroenterology and Hepatology Study of the Effect of Sofosbuvir and Daklatasivir on Respiratory System in Patients with Chronic Hepatitis C Alaa Aboud1, Laila anwer2, Mohammed soliman3 1Department of Tropical Medicine, Beni-Suef University Faculty of Medicine, Benisuef 62511, Egypt; 2Department of Chest, Beni-Suef University Faculty of Medicine; 3Department of radiology,Beni suef university faculty of medicine Background: The aim is to study effect of sofosbuvir and daklatasivir on respiratory system. Patient and methods: A randomized study was done after all patients gave an informed consent before the start. The study population consists of 21 patients receiving treatment of HCV coming to the outpatient clinic of beni suef university hospital. Results: There is no major adverse effect of sofosbuvir and daklatasivir on respiratory system as proved by assessment of pulmonary function and Computed tomography before and after treatment. Keywords: Hepatitis C, DAAs, Chest ...

Liver cirrhosis with high IgG4 in a patient with, diabetes mellitus, ulcerative colitis with papillary thyroid cancer, is it all related ? which one to blame& is it time to raise awareness about IGG4 and hepatobiliary diseases

Research Article of Open Journal of Gastroenterology and Hepatology Liver cirrhosis with high IgG4 in a patient with, diabetes mellitus, ulcerative colitis with papillary thyroid cancer, is it all related ? which one to blame& is it time to raise awareness about IGG4 and hepatobiliary diseases Makki H.Fayadh MRCP UK,FRCP Ed,FRCP London*, Salim Awadh MRCP UK,FRCP London, Tarek Mohamed Badawy, Mahmoud Bahram MD, Ayman Salah Moussa MD, Loai Elkewisny MD, Diaa Eldeeb MD Advanced center for day care surgery Abu Dhabi UAE Back ground: There is possible etiological relation between high IgG4 in a patient with liver cirrhosis, ulcerative colitis, diabetes mellitus , prostatitis ,venous thrombosis and thyroid cancers and the use of immunosuppressive & biologic agents. Method: a study of patient with multiple organ involvement with persistently elevated IgG4. A 56 years old male with persistently elevated IgG4 over 2.5 times normal level, diabetic on insulin, ulcerative colitis on azathioprin & adalimumab developed deep skin pigmentation and liver enzymes elevation with portal hypertension and liver cirrhosis, azathioprine & adalimumab were stopped and golimumab started, after 3 infusions of golimumab papillary thyroid cancer developed .Total thyroidectomy followed by radio iodine after which severe sialo adenitis developed which responded to steroids. His ulcerative colitis was treated with vedolizumab with good response. liver cirrhosis progressed with bleeding varices and portal vein thrombosis with factor Leiden V mutation. Results and conclusions: High IgG4 can be related to many organs including pancreas,liver,thyroid ,small and large bowel,parotid glands ,in this patients all these were affected resulting in colitis,diabetes,liver cirrhosis and thyroid cancer and sialo adenitis. Awareness is needed on the associations with high IgG4. Conclusion: A patient with elevated IgG4 , liver cirrhosis , diabetes mellitus, ulcerative colitis developed skin pigmentation, and papillary thyroid cancer associated with persistently elevated IgG4. Keywords: IgG4 related, liver cirrhosis ...

Dr. Mohammed Naeem
Chair, Patient Safety Reporting/Consultant Pediatric Intensivist/ Head PICU (A)/ Assistant Professor, Dept. of Pediatrics. Ministry National Guard Health Affairs Riyadh, Saudi Arabia

Dr Toru Ishikawa
Gastroenterology, Saiseikai Niigata Daini Hospital

Dr. George Paraskevas
Associate Professor of Anatomy Orthopedic Surgeon, Department of AnatomyMedical School, Aristotle University of Thessaloniki, Post Box: 300, Post Code: 54124, Thessaloniki, Greece

Dr. Mahaboob Vali Shaik
Assistant Professor/Senior Scientist, Department of Genetics & stem cell Research, Narayana Medical College & Hospitals

Dr. Ifeadike Chigozie Ozoemena
Associate Professor, Department of Community Medicine, Faculty of Medicine, Nnamdi Azikiwe University

Dr. Eduardo de Moura GH
Professor, niversity of São Paulo School of Medicine, São Paulo, Brazil

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.Gomes, K.K.L; Lima, A.A.F. Living Style of Diabetic Patients Type.Open Journal of Gastroenterology and Hepatology, 2018, 1:5. DOI:10.28933/ojgh-2018-05-1005

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

Open Journal of Gastroenterology and Hepatology is a peer reviewed open access journal publishing research manuscripts, review articles, editorials, letters to the editor in Gastroenterology and Hepatology  (Indexing information).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions shortly.

Open Journal of Gastroenterology and Hepatology LOGO1

Loading